Annovis Bio Issued European Patent for Method of Treating Alzheimer’s Disease with ANVS401
June 02 2020 - 6:45AM
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug
platform company addressing Alzheimer’s disease (AD), Parkinson’s
disease (PD) and other neurodegenerative diseases, today
announced the European Patent Office (EPO) granted the
Company’s patent for a method of treating Alzheimer’s disease in
humans by administering its lead compound, ANVS401.
“We now have two patents covering our primary disease targets,
AD and PD, both originating from a patent family that claims
ANVS401 for the treatment of neurodegenerative diseases. Pursuant
to our discussions with the US Patent and Trademark Office (USPTO),
we split the original application into a number of patents, each
one covering individual diseases that our drug targets,” commented
Maria Maccecchini, Ph.D., CEO of Annovis. “Based on these
discussions, we have filed additional patent applications for each
individual neurodegenerative disease and expect to receive
additional patent allowances in the coming months. We will
continue to provide further updates as we execute on this
process.”
The USPTO approved the Company’s first PD patent (US 10,383,851)
in August 2019. The EPO approved Annovis Bio’s first AD patent (EP
2683242) on March 12, 2020.
ANVS401 can work in AD and PD because nerve cells die by the
same mechanism in both diseases, and ANVS401 stops the toxic
cascade leading to nerve cell death in both diseases. Capitalizing
on that knowledge, Annovis Bio is running two Phase 2 studies to
show in both patient populations that what was demonstrated in
animals can be reproduced in humans and that ANVS401 protects the
nerve cells from dying, and by doing so, preserves the associated
function.
About Annovis Bio
Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc.
(Annovis) is a clinical-stage, drug platform company addressing
neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s
disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). We believe
that we are the only company developing a drug for AD, PD and AD-DS
that inhibits more than one neurotoxic protein and, thereby,
improves the information highway of the nerve cell, known as axonal
transport. When this information flow is impaired, the nerve cell
gets sick and dies. We expect our treatment to improve memory loss
and dementia associated with AD and AD-DS, as well as body and
brain function in PD. We have an ongoing Phase 2a study in AD
patients and plan to commence a second Phase 2a study in PD and AD
patients. For more information on Annovis, please visit the
company’s website: www.annovisbio.com.
Forward-Looking Statements
Statements in this press release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“expect,” “believe,” “will,” “may,” “should,” “estimate,”
“project,” “outlook,” “forecast” or other similar words, and
include, without limitation, statements regarding the timing,
effectiveness and anticipated results of ANVS401 clinical trials
and the approval of any allowances or additional patents.
Forward-looking statements are based on Annovis Bio, Inc.’s current
expectations and are subject to inherent uncertainties, risks and
assumptions that are difficult to predict. Further, certain
forward-looking statements are based on assumptions as to future
events that may not prove to be accurate. These and other risks and
uncertainties are described more fully in the section titled “Risk
Factors” in the Annual Report on Form 10-K for the year ended
December 31, 2019 filed with the Securities and Exchange
Commission. Forward-looking statements contained in this
announcement are made as of this date, and Annovis Bio, Inc.
undertakes no duty to update such information except as required
under applicable law.
Investor Relations:
Dave Gentry, CEO RedChip Companies Inc. 407-491-4498
Dave@redchip.com
SOURCE: Annovis Bio Inc.
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Sep 2023 to Sep 2024